Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

3-Aryloxy-3-phenylpropylamines and acid addition salts thereof are useful in blocking uptake of monoamines by brain neurons, and are thus effective in treating disorders of sleep, sexual performance, appetite, muscular function, and pituitary function.

Inventors: Bryan B. Molloy, Klaus K. Schmiegel
Original Assignee: Eli Lilly and Company
Current U.S. Classification: 514/651; 564/347
International Classification: A61K 31135

View patent at USPTO
Search USPTO Assignment Database

Citations

Cited PatentFiling dateIssue dateOriginal AssigneeTitle
US2683742Feb 23, 1951Jul 13, 1954ATENT OFFICE
US3106564Aug 21, 1958Oct 8, 1963Z-PHENOXX-Z-PHENYLETHYL
US3132179Aug 27, 1959May 5, 1964CHOOC
US3253040Dec 10, 1962May 24, 1966PROCESS FOR THE PRODUCTION OF PRIMARY J-HYDROCARBYLOXYPROPYLAMENES
US3562330Jul 18, 1968Feb 9, 1971PHENOXY-X. AND S-PHENYL-BUTYL AND -PENTYL-AMINES AND SALTS
US4018895Sep 17, 1975Apr 19, 1977Eli Lilly and CompanyAryloxyphenylpropylamines in treating depression
US4194009Sep 15, 1976Mar 18, 1980Eli Lilly and CompanyAryloxyphenylpropylamines for obtaining a psychotropic effect
US4313896Mar 9, 1981Feb 2, 1982Eli Lilly and CompanyAryloxyphenylpropylamines
US4314081Jan 10, 1974Feb 2, 1982Eli Lilly and CompanyArloxyphenylpropylamines

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US4692469Apr 4, 1986Sep 8, 1987CIBA-GEIGY CorporationPropylamine derivatives
US4824868Jul 17, 1987Apr 25, 1989Ciba-Geigy Corporation
Ciba-Geigy Corporation		Propylamine derivatives useful for the treatment of dementia
US4895845Sep 15, 1986Jan 23, 1990Method of assisting weight loss
US4940585Feb 17, 1989Jul 10, 1990Method for the treatment of nicotine withdrawal syndrome
US4956388Jan 12, 1990Sep 11, 1990Eli Lilly and Company3-aryloxy-3-substituted propanamines
US5104899Aug 13, 1990Apr 14, 1992Sepracor, Inc.Methods and compositions for treating depression using optically pure fluoxetine
US5114976Nov 5, 1990May 19, 1992Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5229417Dec 5, 1991Jul 20, 1993Hoechst-Roussel Pharmaceuticals Incorporated2-(3-phenylpropyl)hydrazines and method of treating personality disorders
US5238959Apr 20, 1992Aug 24, 1993Eli Lilly and Company3-phenyloxy-3-phenyl propanamines
US5250571Apr 21, 1992Oct 5, 1993Eli Lilly and Company(S)-norfluoxetine in method of inhibiting serotonin uptake
US5250572Apr 21, 1992Oct 5, 1993Eli Lilly and Company(R)-norfluoxetine in method for occupying serotonin IC receptors
US5268468May 24, 1993Dec 7, 1993Hoechst-Roussel Pharmaceuticals IncorporatedN-nitrosophenoxybenzenepropanamine and N-1-chloroethyl carbamate intermediates
US5281624Sep 27, 1991Jan 25, 1994Eli Lilly and CompanyN-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5283263Apr 17, 1992Feb 1, 1994Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5397122Feb 28, 1994Mar 14, 1995Golf club swing connecting device
US5525705Jan 31, 1995Jun 11, 1996Eli Lilly and CompanyAnti-obesity proteins
US5527788Jan 18, 1994Jun 18, 1996Louisiana State Univ. Medical Center FoundationMethod and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5532336Jan 31, 1995Jul 2, 1996Eli Lilly and CompanyAnti-obesity proteins
US5552522Jan 31, 1995Sep 3, 1996Eli Lilly and CompanyAnti-obesity proteins
US5552523Feb 6, 1995Sep 3, 1996Eli Lilly and CompanyAnti-obesity proteins
US5552524Feb 6, 1995Sep 3, 1996Eli Lilly and CompanyAnti-obesity proteins
US5554727Feb 6, 1995Sep 10, 1996Eli Lilly and CompanyAnti-obesity proteins
US5563243Jan 31, 1995Oct 8, 1996Eli Lilly and CompanyAnti-obesity proteins
US5563244Jan 31, 1995Oct 8, 1996Eli Lilly and CompanyAnti-obesity proteins
US5563245Jan 31, 1995Oct 8, 1996Eli Lilly and CompanyAnti-obesity proteins
US5567678Jan 31, 1995Oct 22, 1996Eli Lilly and CompanyAnti-obesity proteins
US5567803Feb 6, 1995Oct 22, 1996Eli Lilly and CompanyAnti-obesity proteins
US5569744Feb 6, 1995Oct 29, 1996Eli Lilly and CompanyAnti-obesity proteins
US5574133Jan 31, 1995Nov 12, 1996Eli Lilly and CompanyAnti-obesity proteins
US5580954Jan 31, 1995Dec 3, 1996Eli Lilly and CompanyAnti-obesity proteins
US5589511Apr 15, 1994Dec 31, 1996Sepracor Inc.Method for treating migraine headaches using optically pure S(+) fluoxetine
US5589512Jan 25, 1994Dec 31, 1996Method for treating borderline personality disorder with serotonin re-uptake blockers
US5594101Mar 3, 1995Jan 14, 1997Eli Lilly and CompanyAnti-obesity proteins
US5594104Feb 6, 1995Jan 14, 1997Eli Lilly and CompanyAnti-obesity proteins
US5605886May 17, 1995Feb 25, 1997Eli Lilly and CompanyAnti-obesity proteins
US5648396Jun 7, 1995Jul 15, 1997Sepracor Inc.Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
US5691309Feb 6, 1995Nov 25, 1997Eli Lilly and CompanyAnti-obesity proteins
US5708035May 22, 1995Jan 13, 1998Sepracor Inc.
McLean Hospital		Methods of use and compositions of R(-) fluoxetine
US5719266Mar 17, 1995Feb 17, 1998Eli Lilly and CompanyAnti-obesity proteins
US5744501Mar 11, 1997Apr 28, 1998Method for treating late luteal phase dysphoric disorder
US5789449Sep 19, 1996Aug 4, 1998Treatment of symptoms associated with premenstrual disorders
US5795880Dec 30, 1996Aug 18, 1998Louisiana State University Medical Center FoundationMethod and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5830500Jul 22, 1996Nov 3, 1998Pentech Pharmaceuticals, Inc.Low dose fluoxetine tablet
US5851995Aug 4, 1997Dec 22, 1998Eli Lilly and CompanyAnti-obesity proteins
US5910319May 29, 1997Jun 8, 1999Eli Lilly and CompanyFluoxetine enteric pellets and methods for their preparation and use
US5936124Jun 22, 1998Aug 10, 1999Sepacor Inc.Fluoxetine process from benzoylpropionic acid
US5985322Mar 10, 1999Nov 16, 1999Eli Lilly and CompanyMethod for the treatment of CNS disorders
US6017965Dec 11, 1996Jan 25, 2000NPS Pharmaceuticals, Inc.Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6025517Aug 3, 1998Feb 15, 2000Sepracor Inc.Fluoxetine process from benzoylacetonitrile
US6028224May 24, 1999Feb 22, 2000Sepracor Inc.Fluoxetine process from benzoylpropionic acid
US6203817Jun 5, 1998Mar 20, 2001ALZA CorporationReduction of skin reactions caused by transdermal drug delivery
US6258853Jan 31, 2001Jul 10, 2001Form a of fluoxetine hydrochloride
US6273260Mar 8, 2000Aug 14, 2001Eli Lilly and CompanyPharmaceutical packaging system
US6310250Jan 31, 2001Oct 30, 2001Form A of fluoxetine hydrochloride
US6310251Jan 31, 2001Oct 30, 2001Form a of fluoxetine hydrochloride
US6313350Jan 31, 2001Nov 6, 2001Form a of fluoxetine hydrochloride
US6316672Jan 31, 2001Nov 13, 2001Form a of fluoxetine hydrochloride
US6395509May 26, 1995May 28, 2002Eli Lilly and CompanyDNA encoding Rhesus ob protein
US6492556Nov 5, 2001Dec 10, 2002Form A of fluoxetine hydrochloride
US6512010Jul 14, 1997Jan 28, 2003Alza CorporationFormulations for the administration of fluoxetine
US6982251Jun 11, 2002Jan 3, 2006Schering CorporationSubstituted 2-azetidinones useful as hypocholesterolemic agents
US7011844Nov 22, 2002Mar 14, 2006Alza CorporationFormulations for the administration of fluoxetine
US7030106May 1, 2002Apr 18, 2006Schering CorporationSterol absorption inhibitor compositions
US7034059Jun 28, 2002Apr 25, 2006Sepracor Inc.Methods of using norfluoxetine
US7053080Sep 19, 2002May 30, 2006Schering CorporationMethods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7071181Sep 19, 2002Jul 4, 2006Schering CorporationMethods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7132415Sep 19, 2002Nov 7, 2006Schering CorporationMethods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7189755Feb 10, 2004Mar 13, 2007Palatin Technologies, Inc.Pyrrolidine melanocortin-specific compounds
US7192944Mar 3, 2004Mar 20, 2007Schering Corp.Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486Mar 3, 2004Apr 24, 2007Schering CorporationSubstituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543Mar 3, 2004Jun 26, 2007Schering CorporationSubstituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7268166Feb 13, 2006Sep 11, 2007NPS Pharmaceuticals, Inc.Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7326707Jan 21, 2004Feb 5, 2008Palatin Technologies IncorporatedBicyclic melanocortin-specific compounds
US7326733Jun 2, 2003Feb 5, 2008The Forsyth InstituteMethods for increasing bone density
US7354923Jan 21, 2004Apr 8, 2008Palatin Technologies, Inc.Piperazine melanocortin-specific compounds
US7368562Feb 13, 2007May 6, 2008Schering CorporationSubstituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368563Feb 13, 2007May 6, 2008Schering CorporationSubstituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7378518Feb 20, 2007May 27, 2008Schering CorporationSubstituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7417039Jan 25, 2002Aug 26, 2008Schering CorporationUse of substituted azetidinone compounds for the treatment of sitosterolemia
US7456184Apr 30, 2004Nov 25, 2008Palatin Technologies Inc.Melanocortin receptor-specific compounds
US7459442Apr 24, 2008Dec 2, 2008Schering CorporationSubstituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7560449Nov 4, 2003Jul 14, 2009Schering CorporationMethods and therapeutic combinations for the treatment of demyelination
US7601753Mar 1, 2007Oct 13, 2009Palatin Technologies, Inc.Pyrrolidine melanocortin-specific compounds
US7612058Nov 29, 2004Nov 3, 2009Schering CorporationMethods for inhibiting sterol absorption
US7655658Jan 21, 2005Feb 2, 2010Palatin Technologies, Inc.Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7709484Apr 19, 2005May 4, 2010Palatin Technologies, Inc.Substituted melanocortin receptor-specific piperazine compounds
US7718802Apr 5, 2005May 18, 2010Palatin Technologies, Inc.Substituted melanocortin receptor-specific piperazine compounds
US7727990Aug 11, 2006Jun 1, 2010Palatin Technologies, Inc.Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991Aug 11, 2006Jun 1, 2010Palatin Technologies, Inc.Substituted melanocortin receptor-specific single acyl piperazine compounds
US7732413Apr 24, 2008Jun 8, 2010Schering CorporationSubstituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7732451Jan 14, 2005Jun 8, 2010Palatin Technologies, Inc.Naphthalene-containing melanocortin receptor-specific small molecule
US7741289Apr 22, 2008Jun 22, 2010Schering CorporationSubstituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7807678Feb 10, 2004Oct 5, 2010Palatin Technologies, Inc.Peptidomimetics of biologically active metallopeptides
US7834017Aug 10, 2007Nov 16, 2010Palatin Technologies, Inc.Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US7964601Jun 2, 2008Jun 21, 2011Palatin Technologies, Inc.Melanocortin receptor-specific compounds
US7968548Aug 11, 2006Jun 28, 2011Palatin Technologies, Inc.Melanocortin receptor-specific piperazine compounds with diamine groups
USRE39030Jan 28, 2002Mar 21, 2006Eli Lilly and CompanyFluoxetine enteric pellets and methods for their preparation and use

Claims

1. A method of treating animals suffering from an appetite disorder comprising administering to said animal an effective amount of a compound of the formula ##STR7## wherein each R' is independently hydrogen or methyl; wherein R is naphthyl or ##STR8## wherein R" and R"' are halo, trifluoromethyl, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkyloxy or C.sub.3 -C.sub.4 alkenyl; and

wherein n and m are 0, 1 or 2; and acid addition salts thereof formed with pharmaceutically-acceptable acids.

2. A method according to claim 1 employing N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine or a pharmaceutically-acceptable acid addition salt thereof.

3. The method of claim 2 employing N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine hydrochloride.

4. A method of blocking the uptake of monoamines by brain neurons in animals comprising administering to said animal a monoamine blocking amount of a compound of the formula ##STR9## wherein each R' is independently hydrogen or methyl; wherein R is naphthyl or ##STR10## wherein R" and R"' are halo, trifluoromethyl, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkyloxy or C.sub.3 -C.sub.4 alkenyl; and

wherein n and m are 0, 1 or 2; and acid addition salts thereof formed with pharmaceutically-acceptable acids.

5. A method according to claim 4 wherein the monoamine to be blocked is serotonin.

6. A method according to claim 5 employing N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine or a pharmaceutically-acceptable acid addition salt thereof.

7. The method of claim 6 employing N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine hydrochloride.

8. The method of claim 5 employing N-methyl-3-(o-methylphenoxy)-3-phenylpropylamine or a pharmaceutically-acceptable acid addition salt thereof.

9. The method of claim 5 employing N-methyl-3-(o-methylphenoxy)-3-phenylpropylamine hydrochloride.